Hemophilia is a bleeding disorder that occurs because of deficiencies in coagulation proteins. The proteins involved are factor VIII and factor IX. Hemophilia A occurs when there is a deficiency of factor VIII. Hemophilia B, on the other hand, occurs when results when there is a deficiency of factor IX. Hemophilia affects normal blood clotting which is why bleeding is commonly reported in patients who live the disease. Another common problem reported in people with this disorder is joint problems including joint pain and arthropathy. Arthropathy occurs because bleeding is common in the joints. Bleeding in patients living with hemophilia can also happen in tissues and organs. Estimating the number affected by hemophilia in the US is difficult. However, results from epidemiological studies and surveillance data estimate the total number to be between 30,000 to 33,000. The incidence rate of hemophilia is 1 in every 5000 male births. Addressing the disorder is important because the disease is associated with a significant burden. Several comorbidities are associated with hemophilia. They are liver disease, overweight and obesity, and heart disease. Hemophilia is also associated with significant healthcare costs. Clotting factor replacement therapy and prophylaxis are the mainstay treatment strategies for treating hemophilia. Research has shown that the treatment strategies are effective in addressing hemophilia with lower risk of complications.
No takes yet. Share an insight, caveat, or question.
Pallav Dave (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: